|
Nasal Naloxone Price Set to Jump
MEDPAGE TODAY Eliza Wheeler and several volunteers sit on the floor of her office and pack naloxone kits. They package up rubber gloves, rescue breathing masks, alcohol pads, and two atomizers. And, of course, the key ingredient: two cartridges of nasal naloxone -- an old drug that can reverse an opioid overdose in seconds. Problem is, the price of naloxone is doubling, and community groups like Wheeler's may not be able to afford it. READ MORE ... |
Injecting Opana Tied to Blood Clotting Disorder
|
Benzo 'Boost' Can Be Deadly
|
Can a Genetic Test Predict Opioid Addiction Risk?
|
MORE STORIES:
FDA Panel Splits on Naloxone Dose
Long-Acting Morphine Wins FDA Advisors' Support
Some Spared HIV Infection in Indiana Opana-Related Outbreak
Pfizer's Troxyca Gets Mixed Review from FDA Advisors
FDA Advisors OK Abuse-Deterrent Opioid, Despite Concerns
Novel Opioid Not Abuse-Deterrent, FDA Panel Says
Opioids: Mandate Education for Prescribers
Opioid REMS Impact Unclear
Opioid Crisis: Scrap Pain as 5th Vital Sign?
FDA Releases Draft Plan for Abuse-Deterrent Opioid Generics
Short-Acting Opioids Get New Boxed Warning
HHS Issues Pain Strategy, With No Fanfare
CDC Comes Down Hard on Opioids for Chronic Pain
FDA Science Advisors Talk Strategy on Opioids
Vicodin Scripts Down After Tighter Controls
Docs on Board with CDC Opioid Guidance
Will Delay Weaken CDC Opioid Guidance?
FDA Comments on Nasal Naloxone Dose Concerns
Naloxone for Opioid Overdose: Questions About Dosing
Opioid Overdose Deaths Keep Rising
FDA Panels Like New Abuse-Deterrent Opioid
FDA Panels Nix Roxicodone Reformulation
Purdue Pulls New OxyContin Application, & Questions Follow
On-Label Naloxone in the Works
Abandoned Painkiller Makes a Comeback
Injecting Opana Tied to Blood Clotting Disorder
Congress Pressures FDA to Finalize Opioid Guidance
No Easing in Opioid Death Toll
Scant Evidence for Opioids in Chronic Pain
Nasal Naloxone Price Set to Jump
FDA Okays Abuse-Deterrent Hydrocodone
FDA Focuses on Abuse-Deterrent Opioids
FDA Okays Third Abuse-Deterrent Opioid
Different Dataset, Same Result: Heroin Deaths Rising
AAN Warns Against Opioids in Chronic Pain
‘Abuse-Deterrent’ Label Panned for New Opioid
Opioid, Heroin Deaths Continue to Climb
FDA Panel Snubs Morphine-Oxycodone Combo
FDA Opioid Rulings Slammed
Schumer to HHS: Ditch Zohydro
Senators Investigate Alleged Zohydro Pay-to-Play
Groups Ask FDA to Reconsider Zohydro Approval
Killing Pain: Script by Script // MJS.com
Killing Pain: Fewer Opioid Scripts // MJS.com
Killing Pain: Tranquilizer Nation Timeline
Killing Pain: Xanax Tops Charts // MJS.com
Killing Pain: Benzo ‘Boost’ Can Be Deadly // MJS.com
28 Attorneys General Ask FDA to Reconsider Zohydro Approval
FDA Okays High-Dose Narcotic Painkiller Zohydro, Raising Abuse Concerns // MJS.com
No Abuse Protection in New Painkiller Zohydro // with the Milwaukee Journal Sentinel
FDA Plans to Restrict Vicodin Rx // with the Milwaukee Journal Sentinel
FDA Tightens Reins on Long-Acting Opioids
FDA Allows Opana Generics
FDA Updates OxyContin Label, Blocks Generics
Pain Groups Offer Alternatives to Label Changes
Opioid Labeling Debated at FDA Hearing
FDA Panel Votes for Tighter Controls on Vicodin
Abuse of ‘New’ Opana Linked to Blood Disorder
FDA Unveils Tamper-Resistant Opioid Plan
Abuse Resistance an Issue with Opioid Generics
Vicodin Triggers Interagency War
FDA: Don’t Tighten Vicodin Regulation
Docs Feel Pressure to Give Addicts Opioids
More Addictions Treated with Drug Therapy
Report: Rx Monitoring Plans Flawed
Critis: Opioid REMS Misses Mark on Patient Education
FDA’s Opioid Control Plan Slammed
OxyContin Remake Sends Abusers to Other Opioids
FDA Finalizes Opioid Education Plan
FDA Closes Doors on Unapproved Pain Meds
NY Lawmakers Pass Narcotic Painkiller Bill
New York Clamps Down on Narcotic Painkillers
Feds Analyze, Target Painkiller Abuse
DEA Targets Retailers to Curb Rx Drug Abuse
Physician Group Challenges IOM Pain Report
Rescheduling Hydrocodone
Generic Vicodin Easiest Opioid to Prescribe
Critics Wary of FDA’s REMS for Long-Acting Opioids
White House Targets Painkiller Abuse
Companies Attempt Abuse-Proof Opioids
Deaths from Rx Painkillers Still Rising, CDC Says
Year in Review: Mitigating Opioid Risks
Barriers Remain for Primary Care Tx of Addicts
FDA Panel Splits on Naloxone Dose
Long-Acting Morphine Wins FDA Advisors' Support
Some Spared HIV Infection in Indiana Opana-Related Outbreak
Pfizer's Troxyca Gets Mixed Review from FDA Advisors
FDA Advisors OK Abuse-Deterrent Opioid, Despite Concerns
Novel Opioid Not Abuse-Deterrent, FDA Panel Says
Opioids: Mandate Education for Prescribers
Opioid REMS Impact Unclear
Opioid Crisis: Scrap Pain as 5th Vital Sign?
FDA Releases Draft Plan for Abuse-Deterrent Opioid Generics
Short-Acting Opioids Get New Boxed Warning
HHS Issues Pain Strategy, With No Fanfare
CDC Comes Down Hard on Opioids for Chronic Pain
FDA Science Advisors Talk Strategy on Opioids
Vicodin Scripts Down After Tighter Controls
Docs on Board with CDC Opioid Guidance
Will Delay Weaken CDC Opioid Guidance?
FDA Comments on Nasal Naloxone Dose Concerns
Naloxone for Opioid Overdose: Questions About Dosing
Opioid Overdose Deaths Keep Rising
FDA Panels Like New Abuse-Deterrent Opioid
FDA Panels Nix Roxicodone Reformulation
Purdue Pulls New OxyContin Application, & Questions Follow
On-Label Naloxone in the Works
Abandoned Painkiller Makes a Comeback
Injecting Opana Tied to Blood Clotting Disorder
Congress Pressures FDA to Finalize Opioid Guidance
No Easing in Opioid Death Toll
Scant Evidence for Opioids in Chronic Pain
Nasal Naloxone Price Set to Jump
FDA Okays Abuse-Deterrent Hydrocodone
FDA Focuses on Abuse-Deterrent Opioids
FDA Okays Third Abuse-Deterrent Opioid
Different Dataset, Same Result: Heroin Deaths Rising
AAN Warns Against Opioids in Chronic Pain
‘Abuse-Deterrent’ Label Panned for New Opioid
Opioid, Heroin Deaths Continue to Climb
FDA Panel Snubs Morphine-Oxycodone Combo
FDA Opioid Rulings Slammed
Schumer to HHS: Ditch Zohydro
Senators Investigate Alleged Zohydro Pay-to-Play
Groups Ask FDA to Reconsider Zohydro Approval
Killing Pain: Script by Script // MJS.com
Killing Pain: Fewer Opioid Scripts // MJS.com
Killing Pain: Tranquilizer Nation Timeline
Killing Pain: Xanax Tops Charts // MJS.com
Killing Pain: Benzo ‘Boost’ Can Be Deadly // MJS.com
28 Attorneys General Ask FDA to Reconsider Zohydro Approval
FDA Okays High-Dose Narcotic Painkiller Zohydro, Raising Abuse Concerns // MJS.com
No Abuse Protection in New Painkiller Zohydro // with the Milwaukee Journal Sentinel
FDA Plans to Restrict Vicodin Rx // with the Milwaukee Journal Sentinel
FDA Tightens Reins on Long-Acting Opioids
FDA Allows Opana Generics
FDA Updates OxyContin Label, Blocks Generics
Pain Groups Offer Alternatives to Label Changes
Opioid Labeling Debated at FDA Hearing
FDA Panel Votes for Tighter Controls on Vicodin
Abuse of ‘New’ Opana Linked to Blood Disorder
FDA Unveils Tamper-Resistant Opioid Plan
Abuse Resistance an Issue with Opioid Generics
Vicodin Triggers Interagency War
FDA: Don’t Tighten Vicodin Regulation
Docs Feel Pressure to Give Addicts Opioids
More Addictions Treated with Drug Therapy
Report: Rx Monitoring Plans Flawed
Critis: Opioid REMS Misses Mark on Patient Education
FDA’s Opioid Control Plan Slammed
OxyContin Remake Sends Abusers to Other Opioids
FDA Finalizes Opioid Education Plan
FDA Closes Doors on Unapproved Pain Meds
NY Lawmakers Pass Narcotic Painkiller Bill
New York Clamps Down on Narcotic Painkillers
Feds Analyze, Target Painkiller Abuse
DEA Targets Retailers to Curb Rx Drug Abuse
Physician Group Challenges IOM Pain Report
Rescheduling Hydrocodone
Generic Vicodin Easiest Opioid to Prescribe
Critics Wary of FDA’s REMS for Long-Acting Opioids
White House Targets Painkiller Abuse
Companies Attempt Abuse-Proof Opioids
Deaths from Rx Painkillers Still Rising, CDC Says
Year in Review: Mitigating Opioid Risks
Barriers Remain for Primary Care Tx of Addicts
